Daily Respiratory Research Analysis
Analyzed 114 papers and selected 3 impactful papers.
Summary
Analyzed 114 papers and selected 3 impactful articles.
Selected Articles
1. Continuous Infusion Versus Intermittent Boluses of Cisatracurium in the Early Management of Pediatric Acute Respiratory Distress Syndrome: A Multicenter, Randomized Controlled Trial.
In this multicenter RCT of children with PARDS, a 24-hour continuous cisatracurium infusion improved extubation rates and shortened PICU stay compared with intermittent boluses, with benefits confined to moderate-to-severe disease. Oxygenation metrics (FiO2, mean airway pressure, oxygenation index) also improved by day 7 in the infusion group.
Impact: This trial directly informs neuromuscular blockade strategy in PARDS, demonstrating clinically meaningful improvements limited to moderate-to-severe disease. It fills a pediatric evidence gap where adult data have been conflicting.
Clinical Implications: For moderate-to-severe PARDS, early 24-hour cisatracurium infusion can be considered to improve oxygenation and expedite extubation and PICU discharge, while routine use in mild cases is not supported.
Key Findings
- Continuous cisatracurium infusion increased extubation from mechanical ventilation versus intermittent boluses, after competing risk adjustment.
- Benefits were confined to moderate-to-severe PARDS (extubation SHR 3.25; earlier PICU discharge SHR 3.16).
- By day 7, FiO2, mean airway pressure, and oxygenation index were lower (improved) in the infusion group for moderate-to-severe cases; no benefit in mild PARDS.
Methodological Strengths
- Multicenter randomized controlled design with explicit comparator (continuous infusion vs intermittent boluses).
- Competing risk analyses and objective ventilatory/oxygenation endpoints.
Limitations
- Sample size, blinding, and detailed sedation/ventilator strategies are not specified in the abstract.
- Intervention duration limited to 24 hours; long-term neuromuscular and functional outcomes not reported.
Future Directions: Confirm optimal duration and dosing of continuous NMB in PARDS; assess long-term neuromuscular outcomes and interactions with lung-protective ventilation and prone positioning.
OBJECTIVES: Pediatric acute respiratory distress syndrome (PARDS) is a critical condition associated with considerable morbidity and mortality. Trials in adults showed controversial results about neuromuscular blocking agents (NMBAs) use in adult acute respiratory distress syndrome. With limited data in PARDS, we sought to compare the outcomes of continuous cisatracurium infusion versus intermittent bolus administration in children with PARDS. METHODS: This multicenter randomized controlled study was performed on patients with PARDS. Enrolled patients were categorized into: group I: patients treated with intermittent boluses of cisatracurium and group II: patients treated with intravenous infusion of cisatracurium for 24h. The primary outcome was the duration on mechanical ventilator (MV). Additional results included changes in ventilatory parameters, and length of pediatric intensive care unit (PICU) stay. RESULTS: Group II was associated with a significantly higher extubation from MV compared to group I, after accounting for death as a competing event. This association was confined to moderate-to-severe PARDS (subdistribution hazard ratio (SHR) 3.25, 95% CI 1.69-6.25, p<0.001) and not observed in mild PARDS. Similar with earlier PICU discharge, with stronger effect in moderate-to-severe disease (SHR 3.16, 95% CI 1.64-6.11, p<0.001). By day 7, patients with moderate-to-severe PARDS in group II showed lower fraction of inspired oxygen, mean airway pressure, and oxygenation index. CONCLUSIONS: In PARDS, cisatracurium infusion was associated with better oxygenation, earlier extubation from MV and shorter PICU stay compared to intermittent boluses, with benefits limited to moderate-to-severe disease. Outcomes were similar in mild PARDS.
2. IDSA 2025 Guidelines on the use of vaccines for the prevention of seasonal Influenza infections in immunocompromised patients.
Using a GRADE-based systematic review, IDSA recommends that all immunocompromised individuals aged ≥6 months receive an age-appropriate influenza vaccine for the 2025–2026 season. Evidence shows a 32% reduction in influenza-associated hospitalization with no increased serious adverse events; high-dose or adjuvanted formulations may improve immunogenicity.
Impact: The guideline provides timely, evidence-based vaccination recommendations for a high-risk population with historically limited data, likely influencing preventive strategies across specialties.
Clinical Implications: Clinicians should prioritize influenza vaccination in immunocompromised patients and consider high-dose or adjuvanted vaccines when appropriate; vaccinating close contacts remains an important adjunct.
Key Findings
- Influenza vaccination reduced influenza-associated hospitalization by 32% in immunocompromised populations.
- No increased risk of Guillain-Barré syndrome or serious adverse events was detected.
- High-dose or adjuvanted vaccines may enhance immunogenicity; household contacts should be vaccinated to reduce transmission.
Methodological Strengths
- Systematic review with GRADE assessment of certainty and recommendation strength.
- Focused inclusion of comparative effectiveness and harm data.
Limitations
- Direct evidence in immunocompromised populations remains limited, relying partly on indirect data from older adults.
- Heterogeneity in immunosuppressive conditions and timing complicates generalization; correlates of protection remain undefined.
Future Directions: Prospective effectiveness studies by immunosuppression type and therapy timing; head-to-head trials of high-dose/adjuvanted vs standard vaccines; define correlates of protection in immunocompromised hosts.
Immunocompromised individuals are at heightened risk for severe influenza-related complications, yet vaccine responses may be attenuated due to underlying disease or immunosuppressive therapies. To inform clinical decision-making for the 2025-2026 respiratory virus season, the Infectious Diseases Society of America (IDSA) convened an expert panel to develop rapid evidence-based guidelines on influenza vaccination for immunocompromised adults and children. The panel conducted a systematic review of literature published between August 2023 and July 2025, supplemented by analyses from the Vaccine Integrity Project. Only comparative effectiveness and harm data were included. Certainty of evidence and strength of recommendations were assessed using the GRADE approach. Direct evidence in immunocompromised populations was limited but demonstrated that influenza vaccination reduced influenza-associated hospitalization by 32%. Indirect evidence from older adult populations showed consistent reductions in hospitalization, intensive care admission, and all-cause mortality, supporting applicability to immunocompromised groups. No increased risk of Guillain-Barré syndrome or serious adverse events was detected, and studies evaluating autoimmune or immunocompromising disease exacerbation showed no significant safety concerns. Given moderate certainty of benefit and low likelihood of serious harm, IDSA strongly recommends that all immunocompromised individuals aged ≥6 months receive an age-appropriate 2025-2026 influenza vaccine. Vaccination should be individualized based on underlying conditions, timing of immunosuppressive therapy, and community influenza activity. High-dose or adjuvanted vaccines may offer enhanced immunogenicity. Household contacts should also be vaccinated to reduce transmission risk. Ongoing research is needed to define correlates of protection, optimize vaccine timing, improve real-world effectiveness data, and enhance strategies for patients with blunted immune responses.
3. Poor control of pulmonary viral replication in COVID-19 patients with early respiratory failure.
In 159 invasively ventilated COVID-19 patients sampled within 24 hours of intubation, 60% had replication-competent virus in BAL, and 84.3% had detectable viral RNA; higher RNA and culture positivity were linked to earlier progression to IMV. Despite type I/III interferon expression, innate effector genes were suppressed, delineating a virological phenotype that may benefit from targeted antivirals.
Impact: Defines a lower-airway virological phenotype at intubation with active replication, providing a rationale for timing and selection of antiviral strategies in severe COVID-19.
Clinical Implications: Consider early antiviral strategies targeting pulmonary replication in patients progressing rapidly to IMV; lower-airway sampling may help identify candidates.
Key Findings
- Replication-competent SARS-CoV-2 was confirmed in 60% of BAL samples; viral RNA detected in 84.3% and subgenomic RNA in 71.7%.
- Higher BAL viral RNA levels and culture positivity independently associated with shorter time from symptom onset to IMV initiation.
- Innate immune effector genes were suppressed despite robust type I/III interferon expression; CXCL10 and PDL1 associated with earlier progression.
Methodological Strengths
- Prospective cohort with standardized BAL sampling within 24 hours of intubation.
- Use of culture-based assays to confirm replication-competent virus plus multivariable regression analyses.
Limitations
- Single time-point sampling limits understanding of replication dynamics over time.
- Therapeutic exposures and variant-specific effects are not detailed in the abstract, potentially affecting generalizability.
Future Directions: Randomized trials testing early, lower-airway–targeted antiviral strategies in patients with culture-positive BAL at intubation; longitudinal profiling to map replication-immune dynamics.
BACKGROUND: Severe respiratory failure is the leading cause of intensive care unit (ICU) admission and mortality in critically ill COVID-19 patients. However, whether active viral replication persists in the lower respiratory tract of these patients and contributes to lung injury remains unclear. METHODS: We conducted a prospective cohort study of 159 critically ill COVID-19 patients requiring invasive mechanical ventilation (IMV). A bronchoalveolar lavage (BAL) sample was collected within 24 hours of intubation. SARS-CoV-2 RNA load (N1, N2, E, and subgenomic E) and the expression of 18 host immune-related genes were assessed. A replication-competent virus was detected using a Vero cell culture assay by inoculating cells with BAL samples and monitoring cytopathic effects. SARS-CoV-2 replication was confirmed by RT-qPCR. Association of virological and immunological factors with time from symptom onset to IMV initiation was evaluated using multivariable linear regression. RESULTS: SARS-CoV-2 RNA was detected in 84.3% of BAL samples, and 71.7% were positive for subgenomic E RNA. Replication-competent virus was confirmed in 60% of the samples. High RNA levels and SARS-CoV-2 culture positivity were independently associated with shorter time from symptom onset to IMV initiation, with culture positivity showing the strongest association. Gene expression profiling revealed a marked suppression of innate immune effectors, despite robust expression of type I and type III interferons. CXCL10 and PDL1 were the only genes independently associated with shorter time from symptom onset to IMV initiation. CONCLUSIONS: At the time of IMV initiation, patients with early respiratory failure showed high levels of SARS-CoV-2 RNA and evidence of active viral replication in the lower respiratory tract. This group represents a distinct virological phenotype that could benefit from therapeutic interventions targeting pulmonary viral replication. REGISTRATION: Sub-study of the CIBERESUCICOVID project (NCT04457505).